Evidence map›Paper›PMID 34538296›Full record

ReviewPediatric clinics of North America2021

Pediatric Rheumatologic Effects of COVID-19.

Nivine El-Hor, Matthew Adams

Abstract readReview
In one paragraph

Review in Pediatric clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae.Seminars in respiratory and critical care medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nivine El-HorDepartment of Internal Medicine and Pediatrics, Children's Hospital of Michigan, 4201 St. Antoine, UHC 5C, Detroit, MI 48201, USA.
Matthew AdamsDivision Chief for Pediatric Rheumatology, Department of Pediatrics, Wayne State University School of Medicine, Wayne Pediatrics, 400 Mack Avenue, Detroit, Michigan 48201, USA. Electronic address: matthew.adams2@wayne.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multisystem inflammatory syndrome (MISC) can result from COVID-19 infection in previously healthy children and adolescents. It is potentially life threatening and is treated initially with intravenous immunoglobulin and aspirin but may require anti-inflammatory monoclonal antibody treatment in severe cases. SARS-CoV-2 infection can cause macrophage activation syndrome, chilblains, and flares of existing rheumatologic diseases. The pandemic has led to later presentation of some rheumatologic conditions as parents and patients have avoided health care settings. PubMed and Google scholar have been utilized to review the literature on the rheumatologic conditions resulting from COVID-19 and the current treatment options.

Indexed as

AdolescentChildCOVID-19HumansRheumatic DiseasesSARS-CoV-2Systemic Inflammatory Response SyndromeCOVID-19Intravenous immunoglobulinKawasaki diseaseMultisystem inflammatory syndrome in children (MIS-C)RheumatologySystemic steroids

Identifiers

PMID34538296
PMCPMC8445755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.